1. Home
  2. News

Three startups were selected to participate in the “Kansai Life Science Accelerator Program 2023”

August 18, 2023

The Kansai Life Science Accelerator Program (KLSAP), launched in 2020, aim to support Japanese startup to expand their business overseas by providing the opportunity to participate in the mentoring sessions by expertise in the life science field.

On July 14th, the Kansai Life Science Accelerator Program 2023 pitch event was held in Kobe, and three (3) startups were selected to participate in the KLSAP2023 Accelerator Program this coming fall. The 3-month program, which includes five bi-weekly customized advisory sessions and two presentation advisory sessions, is coordinated by biomedwoRx: Life Sciences Consulting in collaboration with California Life Sciences (CLS). 

3 Startups to participate in
accelerator program from fall

Pitch session

Audience Prize

KLSAP sponsors and startups


【KLSAP2023 Accelerator Program Participating Startups】

*Alphabetical order

FerroptoCure Inc. (Yuji Otsuki, CEO)

The development of Novel anti cancer drug inducing ”Ferroptosis”


ImmuniT Research Inc. (Masafumi Yasukochi, CEO)

Development and operation of “rippleT”, an automated immune profiling system that can predict the effects of immune checkpoint inhibitors using our unique immune cell analysis technology


RegCell Co., Ltd. (Daisuke Ishikawa, COO)

Development of novel Treg cell therapy for autoimmune and inflammatory diseases


KLSAP is part California Life Sciences’ FAST California advisory program, which provides commercialization resources and advice to international clusters seeking to establish US subsidiaries. FAST advisors represent serial entrepreneurs and business experts specializing in clinical development, regulatory affairs, reimbursement, business development, among other areas of focus.

The program will conclude in December with a CLS Innovation Showcase, where the KLSAP companies will virtually present their innovative technologies to potential alliance, development, and investment partners.

About California Life Sciences (CLS): California Life Sciences (CLS) is the state’s most influential and impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, CLS has served the community by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. 

【Kansai Life Science Accelerator Program 2023】

City of Kobe, Foundation for Biomedical Research and Innovation at Kobe
Sysmex Corporation, Celltrion, Inc., Bayer Yakuhin, Ltd, AstraZeneca K.K., Boehringer Ingelheim Japan, Inc., Kyoto University Medical Science and Business Liaison Organization
Participating Organization:
Japan External Trade Organization
Supporting Organizations:
Life Science Innovation Network Japan, KINKI Bio-Industry Development Organization, Osaka Prefectural Government, Sumitomo Mitsui Banking Corporation, Kansai Innovation Initiative, Kyoto Research Park Corp., Biocommunity Kansai, Hyogo Prefectural Government
Kobe Urban Promotion Service
California Life Sciences, biomedwoRx: Life Sciences Consulting